CR
CRW.LSE Craneware Plc
- Market cap
- GBX 362M
- P/E
- 25.0x
- P/B
- 1.51x
- ROE
- 6.2%
- Dividend yield
- 3.18%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CRW.LSE undervalued?
Graham numberCRW.LSE trades 29.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Craneware Plc fundamental analysis
No fundamental analysis for Craneware Plc yet.
Craneware Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Craneware Plc
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. It provides solutions, such as Trisus Pricing Analyzer and Transparency, a solution that optimizes and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity requirements; Trisus Claims Informatics, a retrospecti…
Full company profileCraneware Plc financial statements
Craneware Plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 57.8M | 67.1M | 71.4M | 71.5M | 75.6M | 166M | 174M | 189M | 206M | 206M |
| Gross Profit | 54.2M | 63.7M | 67.0M | 67.0M | 70.2M | 142M | 148M | 162M | 179M | 139M |
| Operating Income | 16.6M | 18.7M | 18.0M | 19.2M | 13.2M | 18.1M | 19.2M | 19.7M | 25.3M | 27.7M |
| EBITDA | 17.3M | 19.5M | 21.9M | 23.9M | 18.5M | 47.5M | 51.6M | 54.3M | 58.6M | 62.3M |
| Net Income | 13.5M | 15.8M | 15.0M | 16.8M | 12.9M | 9.41M | 9.23M | 11.7M | 19.7M | 19.8M |
| EPS | 0.49 | 0.58 | 0.55 | 0.62 | 0.47 | 0.27 | 0.26 | 0.33 | 0.55 | 0.56 |
| Balance Sheet | ||||||||||
| Total Assets | 97.2M | 98.9M | 106M | 116M | 312M | 569M | 577M | 544M | 551M | 524M |
| Total Liabilities | 37.8M | 47.3M | 46.5M | 47.4M | 51.3M | 236M | 249M | 215M | 214M | 204M |
| Shareholders' Equity | 59.4M | 51.6M | 59.8M | 68.4M | 260M | 333M | 328M | 329M | 338M | 320M |
| Cash & Short-term Investments | 53.2M | 52.8M | 47.6M | 47.9M | 236M | 47.2M | 78.5M | 34.6M | 55.9M | 55.1M |
| Total Debt | - | - | - | 2.96M | 2.20M | 116M | 86.7M | 40.1M | 31.7M | 46.8M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 17.9M | 30.0M | 13.5M | 20.7M | 23.5M | 27.0M | 98.7M | 41.9M | 59.9M | 42.7M |
| Capital Expenditure | 4.58M | 4.69M | 10.4M | 9.71M | 10.3M | 14.0M | 15.6M | 17.0M | 491K | 474K |
| Free Cash Flow | 13.3M | 25.3M | 3.03M | 11.0M | 13.2M | 12.9M | 83.2M | 24.9M | 59.4M | 42.3M |
| Ratios | ||||||||||
| ROE | 22.8% | 30.6% | 25.0% | 24.6% | 5.0% | 2.8% | 2.8% | 3.6% | 5.8% | 6.2% |
| ROA | 13.9% | 16.0% | 14.1% | 14.5% | 4.1% | 1.7% | 1.6% | 2.2% | 3.6% | 3.8% |
| Net Profit Margin | 23.4% | 23.6% | 21.0% | 23.5% | 17.1% | 5.7% | 5.3% | 6.2% | 9.6% | 9.6% |
| Debt to Equity | - | - | - | 0.04x | 0.01x | 0.35x | 0.26x | 0.12x | 0.09x | 0.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Craneware Plc dividends
- Dividend yield
- 3.18%
- Forward dividend
- 0.34 GBX
- Payout ratio
- 79.8%
- Ex-dividend date
- Dec 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 15.8M | 0.45 | 79.8% |
| 2025 | USD 13.3M | 0.37 | 67.5% |
| 2024 | USD 12.8M | 0.36 | 109.4% |
| 2023 | USD 12.1M | 0.34 | 131.3% |
| 2022 | USD 13.0M | 0.37 | 137.9% |
| 2021 | USD 9.70M | 0.36 | 75.2% |
| 2020 | USD 9.08M | 0.33 | 53.9% |
| 2019 | USD 8.50M | 0.31 | 56.7% |
| 2018 | USD 7.82M | 0.29 | 49.5% |
| 2017 | USD 6.36M | 0.23 | 47.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Craneware Plc
- Insiders 26.38%
- Institutions 61.37%
- Public & others 12.26%
- Shares outstanding 34.4M
- Free float 22.4M
Craneware Plc company profile
- Company name
- Craneware Plc
- Ticker
- CRW.LSE
- ISIN
- GB00B2425G68
- Exchange
- London Exchange
- Listed since
- Sep 13, 2007
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 808
- Fiscal year end
- June
- Address
- 1 Tanfield, Edinburgh, United Kingdom, EH3 5DA
- Phone
- 44 13 1550 3100
- Website
- thecranewaregroup.com
About Craneware Plc
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. It provides solutions, such as Trisus Pricing Analyzer and Transparency, a solution that optimizes and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity requirements; Trisus Claims Informatics, a retrospective charge capture analytical application; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit solution for government and commercial payors. The company also offers Trisus Decision Support; Trisus Labor Productivity, which enables healthcare providers to manage, analyze, and plan the deployment of workforce; Trisus Medication Analytic solutions that prioritize, diagnose, and resolve issues in medication systems; and Trisus Supplies Assistant solutions which supplies charged data. In addition, it provides Sentrex, a SaaS-based solution that helps covered entities expand medication access; Sentinel, that tracks all drug activity; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, the company offers professional, pharmacy professional, and appeal services. Additionally, the company provides The Academy, an interactive learning center for user training; Trisus Pricing Integrity Suite; Trisus Business of Pharmacy Suite, which offers solutions centered on each link in the medication revenue cycle; Trisus Value-based Margin and Productivity Suite; and Trisus Data Integrity Suite, which creates a proactive workflow that aligns data between operating units, the supply chain and revenue cycle. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
Craneware Plc management
9- Mr. Keith NeilsonCo-Founder, CEO & Executive Director · born 1969
- Mr. Craig Thomas Preston ACACFO, Company Secretary & Executive Director · born 1970
- Ms. Isabel UrquhartChief People Officer & Director · born 1968
- Mr. Abhilesh GandhiGroup Chief Technology Officer
- Mr. Eric CarterChief Legal Officer
- Ms. Lidia A. Rodriguez-HuppChief Customer Officer
- Ms. Tara HanuscakChief Transformation Officer
- Mr. Ian ArmstrongChief Growth Officer
- Jill GoldsmithCompany Secretary